This work is aimed to develop a simple, precise and accurate HPLC method for the assay of Aliskiren and Valsartan. Aliskiren hemifumarate is a direct renin inhibitor and is indicated for essential hypertension. Valsartan is a nonpeptide specific angiotensin II receptor blocker and is indicated for the treatment of hypertension. The combination of Aliskiren and Valsartan is indicated for the treatment of hypertension. Hence the objective of this research work is to develop and validate a HPLC method for the simultaneous estimation of Aliskiren and Valsartan in bulk drug and pharmaceutical dosage forms as per ICH guidelines. Various trials were carried out for the optimization of the HPLC method for simultaneous estimation of Aliskiren and Valsartan.